These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37464375)

  • 41. Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data.
    Alburquerque-González B; López-Abellán MD; Luengo-Gil G; Montoro-García S; Conesa-Zamora P
    Methods Mol Biol; 2022; 2547():165-185. PubMed ID: 36068464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
    Zheng Y; Fu Y; Wang PP; Ding ZY
    Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Challenges and advances towards the rational design of mRNA vaccines.
    Pollard C; De Koker S; Saelens X; Vanham G; Grooten J
    Trends Mol Med; 2013 Dec; 19(12):705-13. PubMed ID: 24138818
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoantigens and their clinical applications in human gastrointestinal cancers.
    Eshkiki ZS; Agah S; Tabaeian SP; Sedaghat M; Dana F; Talebi A; Akbari A
    World J Surg Oncol; 2022 Sep; 20(1):321. PubMed ID: 36171610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
    Nakajima H; Nakatsura T
    Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. mRNA-based cancer therapeutics.
    Liu C; Shi Q; Huang X; Koo S; Kong N; Tao W
    Nat Rev Cancer; 2023 Aug; 23(8):526-543. PubMed ID: 37311817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. mRNA vaccines for cancer immunotherapy.
    Vishweshwaraiah YL; Dokholyan NV
    Front Immunol; 2022; 13():1029069. PubMed ID: 36591226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Research progress of neoantigens in gynecologic cancers.
    Song Y; Zhang Y
    Int Immunopharmacol; 2022 Nov; 112():109236. PubMed ID: 36113318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
    Lorentzen CL; Haanen JB; Met Ö; Svane IM
    Lancet Oncol; 2022 Oct; 23(10):e450-e458. PubMed ID: 36174631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference.
    Sæbøe-Larssen S; Sioud M
    Methods Mol Biol; 2020; 2115():249-258. PubMed ID: 32006405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment.
    Bastien JP; Minguy A; Dave V; Roy DC
    Semin Immunol; 2019 Apr; 42():101306. PubMed ID: 31604534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of neoantigens: from identification in cancer cells to application in cancer vaccines.
    Ebrahimi N; Akbari M; Ghanaatian M; Roozbahani Moghaddam P; Adelian S; Borjian Boroujeni M; Yazdani E; Ahmadi A; Hamblin MR
    Expert Rev Vaccines; 2022 Jul; 21(7):941-955. PubMed ID: 34196590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy.
    Devi GR; Nath S
    Methods Mol Biol; 2016; 1428():231-43. PubMed ID: 27236803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Personalized cancer vaccines.
    Jain KK
    Expert Opin Biol Ther; 2010 Dec; 10(12):1637-47. PubMed ID: 20979567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer.
    Cafri G; Gartner JJ; Zaks T; Hopson K; Levin N; Paria BC; Parkhurst MR; Yossef R; Lowery FJ; Jafferji MS; Prickett TD; Goff SL; McGowan CT; Seitter S; Shindorf ML; Parikh A; Chatani PD; Robbins PF; Rosenberg SA
    J Clin Invest; 2020 Nov; 130(11):5976-5988. PubMed ID: 33016924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy.
    Cannon MJ; Block MS; Morehead LC; Knutson KL
    Immunotherapy; 2019 Feb; 11(2):75-79. PubMed ID: 30730268
    [No Abstract]   [Full Text] [Related]  

  • 60. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.